Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer
Eur J Pharmacol. 2024 Feb 23:176424. doi: 10.1016/j.ejphar.2024.176424. Online ahead of print.ABSTRACTThe therapeutic landscape of estrogen receptor (ER)-positive breast cancer includes endocrine treatments with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). Fulvestrant is the first approved SERD with proven efficacy and good tolerability in clinical practice. However, secondary drug resistance, low receptor affinity, and parental administration stimulated the search for new oral SERDs opening a new therapeutic era in ER + breast cancer. Elaces...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Giorgio Guglielmi Marzia Del Re Leila Sadeghi Gol Carmelo Bengala Romano Danesi Stefano Fogli Source Type: research
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer
Eur J Pharmacol. 2024 Feb 23:176424. doi: 10.1016/j.ejphar.2024.176424. Online ahead of print.ABSTRACTThe therapeutic landscape of estrogen receptor (ER)-positive breast cancer includes endocrine treatments with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). Fulvestrant is the first approved SERD with proven efficacy and good tolerability in clinical practice. However, secondary drug resistance, low receptor affinity, and parental administration stimulated the search for new oral SERDs opening a new therapeutic era in ER + breast cancer. Elaces...
Source: European Journal of Pharmacology - February 25, 2024 Category: Drugs & Pharmacology Authors: Giorgio Guglielmi Marzia Del Re Leila Sadeghi Gol Carmelo Bengala Romano Danesi Stefano Fogli Source Type: research
Concurrent factors associated with adherence to adjuvant endocrine therapy among women with non-metastatic breast cancer
ConclusionsMedication-taking self-efficacy and employment status were associated with AET adherence above other related factors.Implications for Cancer SurvivorsEnhancing patients ’ confidence in their ability to take AET for breast cancer may represent an important intervention target to boost adherence. (Source: Journal of Cancer Survivorship)
Source: Journal of Cancer Survivorship - February 24, 2024 Category: Cancer & Oncology Source Type: research
Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women
CONCLUSIONS: Patients with breast cancer may have changed body composition and BMD. Compared with the healthy population, the main indicators of osteoporosis in patients with breast cancer were reduced nonadipose tissue, increased risk of edema, altered fat distribution, and reduced BMD. In addition to age, duration of treatment, and duration of menopause, body composition-related indicators such as BMI and basal metabolism may be considerably associated with BMD of patients with breast cancer, suggesting that BMD status can be monitored in clinical practice by focusing on changes in the aforementioned indexes, which may p...
Source: Clinical Breast Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Fang Zhao Chaofan Li Weiwei Wang Yu Zhang Peizhuo Yao Xinyu Wei Yiwei Jia Shaonong Dang Shuqun Zhang Source Type: research
Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women
CONCLUSIONS: Patients with breast cancer may have changed body composition and BMD. Compared with the healthy population, the main indicators of osteoporosis in patients with breast cancer were reduced nonadipose tissue, increased risk of edema, altered fat distribution, and reduced BMD. In addition to age, duration of treatment, and duration of menopause, body composition-related indicators such as BMI and basal metabolism may be considerably associated with BMD of patients with breast cancer, suggesting that BMD status can be monitored in clinical practice by focusing on changes in the aforementioned indexes, which may p...
Source: Clinical Genitourinary Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Fang Zhao Chaofan Li Weiwei Wang Yu Zhang Peizhuo Yao Xinyu Wei Yiwei Jia Shaonong Dang Shuqun Zhang Source Type: research
The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast
CONCLUSIONS: Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.PMID:38393465 | DOI:10.1007/s11033-023-09119-4 (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - February 23, 2024 Category: Molecular Biology Authors: Sneha Pandithar Daniel Galke Ahone Akume Artem Belyakov Dominick Lomonaco Amirah A Guerra Jay Park Olivia Reff Kideok Jin Source Type: research
The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast
CONCLUSIONS: Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.PMID:38393465 | DOI:10.1007/s11033-023-09119-4 (Source: Mol Biol Cell)
Source: Mol Biol Cell - February 23, 2024 Category: Molecular Biology Authors: Sneha Pandithar Daniel Galke Ahone Akume Artem Belyakov Dominick Lomonaco Amirah A Guerra Jay Park Olivia Reff Kideok Jin Source Type: research
Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women
CONCLUSIONS: Patients with breast cancer may have changed body composition and BMD. Compared with the healthy population, the main indicators of osteoporosis in patients with breast cancer were reduced nonadipose tissue, increased risk of edema, altered fat distribution, and reduced BMD. In addition to age, duration of treatment, and duration of menopause, body composition-related indicators such as BMI and basal metabolism may be considerably associated with BMD of patients with breast cancer, suggesting that BMD status can be monitored in clinical practice by focusing on changes in the aforementioned indexes, which may p...
Source: Clinical Breast Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Fang Zhao Chaofan Li Weiwei Wang Yu Zhang Peizhuo Yao Xinyu Wei Yiwei Jia Shaonong Dang Shuqun Zhang Source Type: research
Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women
CONCLUSIONS: Patients with breast cancer may have changed body composition and BMD. Compared with the healthy population, the main indicators of osteoporosis in patients with breast cancer were reduced nonadipose tissue, increased risk of edema, altered fat distribution, and reduced BMD. In addition to age, duration of treatment, and duration of menopause, body composition-related indicators such as BMI and basal metabolism may be considerably associated with BMD of patients with breast cancer, suggesting that BMD status can be monitored in clinical practice by focusing on changes in the aforementioned indexes, which may p...
Source: Clinical Genitourinary Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Fang Zhao Chaofan Li Weiwei Wang Yu Zhang Peizhuo Yao Xinyu Wei Yiwei Jia Shaonong Dang Shuqun Zhang Source Type: research
The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast
CONCLUSIONS: Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.PMID:38393465 | PMC:PMC10891235 | DOI:10.1007/s11033-023-09119-4 (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - February 23, 2024 Category: Molecular Biology Authors: Sneha Pandithar Daniel Galke Ahone Akume Artem Belyakov Dominick Lomonaco Amirah A Guerra Jay Park Olivia Reff Kideok Jin Source Type: research
GSE251644 Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence
In conclusion, our work reveals that CAFs directly control the luminal breast cancer phenotype by selectively modulating ER-α expression and transcriptional function, and further proposes novel targ ets to disrupt the crosstalk between CAFs and tumor cells to reinstate treatment response to endocrine therapy in patients. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - February 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women
ConclusionsPatients with breast cancer may have changed body composition and BMD. Compared with the healthy population, the main indicators of osteoporosis in patients with breast cancer were reduced nonadipose tissue, increased risk of edema, altered fat distribution, and reduced BMD. In addition to age, duration of treatment, and duration of menopause, body composition-related indicators such as BMI and basal metabolism may be considerably associated with BMD of patients with breast cancer, suggesting that BMD status can be monitored in clinical practice by focusing on changes in the aforementioned indexes, which may pro...
Source: Journal of Cancer Research and Clinical Oncology - February 23, 2024 Category: Cancer & Oncology Source Type: research
Recommendations for cyclin ‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)
Oncol Lett. 2024 Feb 8;27(4):145. doi: 10.3892/ol.2024.14278. eCollection 2024 Apr.ABSTRACTBreast cancer is most frequently diagnosed among women aged 65-74 years and the prevalence of comorbidities in elderly patients with breast cancer is 32.2%. In addition, polypharmacy is quite common in these patients. Understanding the interaction between breast cancer treatment modalities and comorbidities is important, particularly in elderly patients, as comorbidities affect the choice of appropriate treatment and are independent risk factors for survival. A total of three oral cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i),...
Source: Oncology Letters - February 22, 2024 Category: Cancer & Oncology Authors: Mehmet Teomete Devrim Cabuk Taner Korkmaz Selcuk Seber Ozge Fulya Ozturk Birkan Aver Atila Karaalp Gul Basaran Source Type: research
